There was no difference in survival between an initial strategy of percutaneous coronary intervention (PCI) plus medical therapy and medical therapy alone in patients with stable ischemic heart disease during an extended-follow-up of up to 15 years in the US. Between June 1999 and January 2004, 2287 patients with stable ischemic heart disease were randomly assigned to an initial management strategy of optimal medical therapy alone (medical-therapy group) or optimal medical therapy plus PCI (PCI group) and no significant difference in the rate of survival was found during a median follow-up of 4.6 years. Extended survival information was available for 1211 patients (53% of the original population). The median duration of follow-up for all patients was 6.2 years (range, 0 to 15); the median duration of follow-up for patients at the sites that permitted survival tracking was 11.9 years (range, 0 to 15). A total of 561 deaths (180 during the follow-up period in the original trial and 381 during the extended follow-up period) occurred: 284 deaths (25%) in the PCI group and 277 (24%) in the medical-therapy group. Source: http://www.nejm.org/
美国长达15年的延长随访中，经皮冠脉介入治疗加上药物治疗与单纯药物治疗对病情稳定的缺血性心脏病的生存率无明显差异。 1999年6月和2004年1月间，2287例稳定的缺血性心脏病患者随机分配到单纯最佳药物治疗（药物治疗组）或最佳药物治疗+ 经皮冠脉介入治疗（经皮冠脉介入治疗组），在中位随访4.6年中未发现生存率有显著差异。共1211名患者（原人口的53％）有延长生存资料。包括所有患者的中位随访时间为6.2年（范围为0〜15年）; 在允许跟踪生存状态的单位，中位随访时间为11.9年（范围为0〜15年）。总共有561人死亡（原试验随访期间180人，延长随访期间381人）：经皮冠脉介入治疗组284人死亡（25％)，药物治疗组277人死亡（24％）。来源：http://www.nejm.org/